Follow The Filings

IPSC Century Therapeutics Inc.

Health Care, filed as CENTURY THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 1.1%
  • $5.9M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Century Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 1.1% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 1.1%

Who owns IPSC

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 1.1%, was 1.3% Reduce −1.4% 2,400,458 $5.9M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IPSC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IPSC insider trades
  • $97K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Chad Cowan Chief Scientific Officer
    Buy
    $49K 58,060 shares at $0.8500 +5.9% to stake
    Traded Dec 22, 2025 Filed Dec 29, 2025
    ↗
  2. Brent Pfeiffenberger CEO
    Buy
    $30K 52,000 shares at $0.5800 +1.6% to stake
    Traded Dec 12, 2025 Filed Dec 16, 2025
    ↗
  3. Brent Pfeiffenberger CEO
    Buy
    $17K 35,000 shares at $0.5000 +1.1% to stake
    Traded Nov 19, 2025 Filed Nov 20, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 sales to cover taxes, 14 share withholdings for taxes, and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B7 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A FORM DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.24M $6.59M $109.16M
Net income -$136.67M -$126.57M -$9.58M
Net margin * -6115.1% -1920.9% -8.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $176.99M $194.05M $120.77M
Total non-current assets * $183.7M $159.16M $102.94M
Total assets $360.69M $353.22M $223.7M
Total current liabilities $17.85M $129.78M $20.23M
Total non-current liabilities * $158.1M $62.07M $44.54M
Total equity $184.75M $161.36M $158.94M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$88.35M -$110.14M -$103.88M
Cash from investing $61.13M $47.48M $107.5M
Cash from financing -$9.72M $74.56M $0.173M
Net change in cash * -$36.94M $11.91M $3.8M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.